Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda

Open access
Ocan, Moses, Nakalembe, Loyce, Otike, Caroline, Mordecai, Tayebwa, Birungi, Joan, Nsobya, Sam · 2024 · Malaria Journal

Published version of a preprint

Abstract

Background: Malaria treatment in sub-Saharan Africa is faced with challenges including unreliable supply of efficacious agents, substandard medicines coupled with high price of artemisinin-based combinations. This affects access to effective treatment increasing risk of malaria parasite resistance development and adverse drug events. This study investigated access to quality-assured artemisinin-based combination therapy (QAACT) medicines among clients of selected private drug-outlets in Uganda. Methods: This was a cross sectional study where exit interviews were conducted among clients of private drug outlets in low and high malaria transmission settings in Uganda. This study adapted the World Health Organization/Health Action International (WHO/HAI) standardized criteria. Data was collected using a validated questionnaire. Data entry screen with checks was created in Epi-data ver 4.2 software and data entered in duplicate. Data was transferred to STATA ver 14.0 and cleaned prior to analysis. The analysis was done at 95% level of significance. Results: A total of 1114 exit interviews were conducted among systematically sampled drug outlet clients. Over half, 54.9% (611/1114) of the participants were males. Majority, 97.2% (1083/1114) purchased an artemisinin-based combination anti-malarial. Most, 55.5% (618/1114) of the participants had a laboratory diagnosis of malaria. Majority, 77.9% (868/1114) of the participants obtained anti-malarial agents without a prescription. Less than a third, 27.7% (309/1114) of the participants obtained a QAACT. Of the participants who obtained QAACT, more than half 56.9% (173/309) reported finding the medicine expensive. The predictors of accessing a QAACT anti-malarial among drug outlet clients include type of drug outlet visited (aPR = 0.74; 95%CI 0.6, 0.91), not obtaining full dose (3-day treatment) of ACT (aPR = 0.49; 95%CI 0.33, 0.73), not finding the ACT expensive (aPR = 1.24; 95%CI 1.03, 1.49), post-primary education (aPR = 1.29; 95%CI 1.07,1.56), business occupation (aPR = 1.24; 95%CI 1.02,1.50) and not having a prescription (aPR = 0.76; 95%CI 0.63, 0.92). Conclusion: Less than a third of the private drug outlet clients obtained a QAACT for management of malaria symptoms. Individuals who did not find artemisinin-based combinations to be expensive were more likely to obtain a QAACT anti-malarial. The Ministry of Health needs to conduct regular surveillance to monitor accessibility of QAACT anti-malarial agents under the current private sector copayment mechanism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-024-04956-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 5

  1. WHO. World malaria report 2022. Geneva: World Health Organization; 2022.
  2. Ministry of Health. Uganda national malaria control policy. Kampala: Ministry of Health; 2011.
  3. Uganda Bureau of Statistics. Uganda national household survey 2016/17. Kampala: Uganda Bureau of Statistics; 2017.
  4. WHO. The global fund to fight AIDS TaM: affordable medicines facility-malaria. Geneva: World Health Organization; 2008.
  5. WHO/Health Action International. Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization; 2008.

Cited by

See all 7

Metadata

Authors
Ocan, M., Nakalembe, L., Otike, C., Mordecai, T., Birungi, J., & Nsobya, S.
Affiliations
  • Makerere University (UG)
  • Soroti University (UG)
  • Joint Clinical Research Centre (UG)
Corresponding author
Ocan, Moses
Venue
Malaria Journal
Published
2024-04-30
Volume
23
Issue
1
Pages
128-128
ISSN
1475-2875 (ISSN-L)
OpenAlex
W4396496040
Cited by
5
References
16
Citations by year
2026: 1 · 2025: 3 · 2024: 1
FWCI
2.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
European and Developing Countries Clinical Trials Partnership (TMA2019CDF-2662 Pfkelch13 emergence)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
artemisinin-based combination therapy, malaria treatment, prescription requirement, self-medication, drug pricing, Uganda, post-primary education, medication adherence, substandard medicines
MeSH terms
Adolescent, Adult, Aged, Antimalarials, Cross-Sectional Studies, Drug Therapy, Combination, Female, Health Services Accessibility, Humans, Malaria, Male, Middle Aged, Surveys and Questionnaires, Uganda, Artemisinins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda. https://app.cochat.ai/papers/10.1186/s12936-024-04956-5
The paper
Ocan, M., Nakalembe, L., Otike, C., Mordecai, T., Birungi, J., & Nsobya, S. (2024). Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda. Malaria Journal. https://doi.org/10.1186/s12936-024-04956-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.